ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (�HighTide�), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
Mr. Ripley has 25 years of experience in pharmaceutical business development. Most recently he served as Head of Global Business Development for Alpha Biopharma. Mr. Ripley will report to Dr. Liping Liu, Chief Executive Officer of HighTide.
�We are very pleased to welcome Dan to the HighTide leadership team. He will play a central role in implementing and executing our global business development and partnership strategy. Dan�s proven track record of cultivating biopharma partnerships and strategic deals will help drive the tremendous opportunities ahead of us as we continue advancing and expanding our pipeline,� said Dr. Liping Liu, Founder and CEO of HighTide.
�I am excited about joining the experienced and dedicated HighTide team,� said Mr. Ripley. �The potential impact of HighTide�s pipeline to improve patients� lives is significant, and it is an honor to help bring these solutions to patients.�
During his tenure at Alpha Biopharma, Mr. Ripley led partnering and in-license asset evaluation, including closing an exclusive license and collaboration agreement with Wugen Inc. for Greater China. Prior to Alpha Biopharma, Mr. Ripley served in several senior business development roles. As Senior VP of Business Development, Program and Alliance Management at Conatus Pharmaceuticals, Mr. Ripley drove international partnering strategies and negotiated a transformational global development and commercialization agreement with Novartis to develop emricasan for nonalcoholic steatohepatitis (NASH). Prior to Conatus, Mr. Ripley was Senior Director, Business Development at Apricus Biosciences and Director, Business Development at Ionis Pharmaceuticals. Mr. Ripley holds a Bachelor of Science degree in Microbiology and Master of Business Administration, Finance from San Diego State University.
About HighTide Therapeutics
HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company�s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project. For more information, please visit www.hightidetx.com.
Contacts
Jeffrey Dao
[email protected]
+1-650-580-3872
